TBPH Theravance Biopharma, Inc. - Or

32.98
-0.06  -0.18%
Previous Close 33.04
Open 33.52
Price To book 5.33
Market Cap 1.71B
Shares 51,942,000
Volume 296,912
Short Ratio 13.10
Av. Daily Volume 513,911

SEC filingsSee all SEC filings

  1. 8-K - Current report 17515679
  2. CT ORDER - Confidential treatment order 162067610
  3. 8-K - Current report 161996307
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 161986777
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161982416

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data due mid-2017.
TD-9855
nOH
Phase 3 study completion due 2018.
Closed Triple
Asthma
NDA filing submission announced November 21, 2016.
Closed Triple
COPD
Phase 3 trials met primary endpoint. 12 month safety trial data (mid-2017) and NDA filing end of 2017.
Revefenacin
COPD
Phase 2b initiated mid March 2015. Data due mid-2017.
Velusetrag (TD-5108)
Gastroparesis
Phase 2 data released June 2016
TD-6450
Hepatitis C virus (HCV)
Phase 3 data due 2018
Telavancin
Bacteremia
Phase 3 first patient enrolled late February 2015. Data due 2017
Telavancin
Staphylococcus aureus bacteremia
Phase 3 data due in 2016
TD-4208
Chronic obstructive pulmonary disease (COPD

Latest News

  1. THERAVANCE BIOPHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  2. The Zacks Analyst Blog Highlights: ELEMENTS SPECTRUM Large Cap U.S. Sector Momentum Index ETN, Advanced Micro Devices, AK Steel Holdings, Theravance Biopharma and Fairmount Santrol Holdings
  3. Coverage initiated on Theravance Biopharma by Needham
  4. Theravance Biopharma Highlights Initiation of Phase 3 Study of the Closed Triple in Patients with Asthma by GlaxoSmithKline and Innoviva
  5. Favorite Healthcare Stocks of Billionaire Seth Klarman’s Baupost Group
  6. Theravance Biopharma, Inc. breached its 50 day moving average in a Bullish Manner : TBPH-US : December 12, 2016
  7. Michael Burry: Current Holdings and a Change of Style
  8. Is Theravance Biopharma Inc (TBPH) A Good Stock To Buy?
  9. Theravance Stock Up on Fast Track Status for Velusetrag
  10. Theravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis
  11. Theravance Biopharma Highlights Filing of EU Regulatory Submission for the Closed Triple in COPD by GlaxoSmithKline and Innoviva
  12. Theravance Biopharma to Present at the 28th Annual Piper Jaffray Healthcare Conference
  13. Here’s Our Take On Theravance Biopharma Inc (TBPH) And GlaxoSmithKline PLC (ADR) (GSK)’s Latest Submission
  14. Theravance Biopharma Highlights Filing of U.S. New Drug Application for the Closed Triple in COPD by GlaxoSmithKline and Innoviva
  15. THERAVANCE BIOPHARMA, INC. Financials
  16. ETFs with exposure to Theravance Biopharma, Inc. : November 15, 2016
  17. THERAVANCE BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  18. Theravance Biopharma, Inc. :TBPH-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016
  19. Theravance Biopharma, Inc. breached its 50 day moving average in a Bullish Manner : TBPH-US : November 14, 2016
  20. Edited Transcript of TBPH earnings conference call or presentation 8-Nov-16 10:00pm GMT

SEC Filings

  1. 8-K - Current report 17515679
  2. CT ORDER - Confidential treatment order 162067610
  3. 8-K - Current report 161996307
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 161986777
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161982416
  6. 8-K - Current report 161981376
  7. 8-K - Current report 161968830
  8. 424B5 - Prospectus [Rule 424(b)(5)] 161959805
  9. 424B5 - Prospectus [Rule 424(b)(5)] 161959804
  10. FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses 161956848